No Prescription |
 |
 | ||
|
TRIQUILAR Ortho Novum 777 |
|
| ||
No Prescription » Prescription Drugs 16 » TRIQUILAR Ortho Novum 777 This medication is used to prevent pregnancy. This medication contains 2 hormones (levonorgestrel a progestin and ethinyl estradiol an estrogen). These hormones prevent pregnancy by preventing the release of an egg (ovulation) and changing the womb and cervical mucus to make it more difficult for an egg to meet sperm (fertilization) or attach to the wall of the womb (implantation).Using this medication does not protect you or your partner against sexually transmitted diseases (e.g. HIV gonorrhea). Buy TRIQUILAR Ortho Novum 777 and other Prescription Drugs 16 products online at Medstore. 973
About TRIQUILAR Ortho Novum 777: Product Type: Prescription Drugs 16 TRIQUILAR ( Ortho-Novum 777 TriNovum ED Generic Levonorgestrel/Ethinylestradiol) TRIQUILAR (Ortho-Novum 777 TriNovum ED Generic Levonorgestrel/Ethinylestradiol) Ortho-Novum 777 TriNovum ED Generic Levonorgestrel/Ethinylestradiol 1 Unit 63 (3 x 21) Ortho-Novum 777 TriNovum ED Generic Levonorgestrel/Ethinylestradiol TRIQUILAR
View more Prescription Drugs 16 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
